Open access
Modified Newcastle Regimen Improves Survival Despite Central Nervous System Relapse in Monomorphic Epitheliotropic Intestinal T‐Cell Lymphoma
M. Suh
Hyungwoo Cho
H. Go
Jin-Sook Ryu
Shin Kim
Kyoungmin Lee
E. J. Chae
C. Park
In Hye Song
Kyung Won Kim
S. Lim
I. Park
Chan Wook Kim
Yong Sik Yoon
J. Hyung
D. H. Yoon
Medicine
Abstract
Monomorphic epitheliotropic intestinal T‐cell lymphoma (MEITL) is a rare, aggressive malignancy with a median overall survival (OS) of 7–15 months. The Newcastle regimen, comprising cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), ifosfamide, etoposide, and epirubicin (IVE), and intermediate‐dose methotrexate for central nervous system (CNS) prophylaxis, has demonstrated promising outcomes in enteropathy‐associated T‐cell lymphoma (EATL) but has not been evaluated in MEITL, where the CNS relapse risk informing methotrexate use remains poorly characterized.